Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

[Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].

Menkiszak J, Chudecka-Głaz A, Gronwald J, Bedner R, Cymbaluk-Płoska A, Wezowska M, Zielińska D, Rzepka-Górska I.

Ginekol Pol. 2013 Sep;84(9):758-64. Polish.

PMID:
24191513
2.

Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.

Menkiszak J, Chudecka-Głaz A, Gronwald J, Cymbaluk-Płoska A, Celewicz A, Świniarska M, Wężowska M, Bedner R, Zielińska D, Tarnowska P, Jakubowicz J, Kojs Z.

J Ovarian Res. 2016 Feb 29;9:11. doi: 10.1186/s13048-016-0220-4.

3.

Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.

Hirasawa A, Masuda K, Akahane T, Tsuruta T, Banno K, Makita K, Susumu N, Jinno H, Kitagawa Y, Sugano K, Kosaki K, Aoki D.

Jpn J Clin Oncol. 2013 May;43(5):515-9. doi: 10.1093/jjco/hyt036. Epub 2013 Mar 13.

PMID:
23487443
4.

Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.

Kim SI, Lim MC, Lee DO, Kong SY, Seo SS, Kang S, Lee ES, Park SY.

J Cancer Res Clin Oncol. 2016 Jan;142(1):333-40. doi: 10.1007/s00432-015-2051-x. Epub 2015 Oct 5.

PMID:
26438354
5.
6.

Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.

Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doorn HC, Gomez Garcia EB, Kets CM, van Leeuwen FE, Meijers-Heijboer HE, Mourits MJ, van Os TA, Vasen HF, Verhoef S, Rookus MA, Hooning MJ; Hereditary Breast and Ovarian Cancer Research Group Netherlands.

J Natl Cancer Inst. 2015 Mar 18;107(5). pii: djv033. doi: 10.1093/jnci/djv033. Print 2015 May.

PMID:
25788320
7.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

9.

Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.

Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH.

J Clin Oncol. 2005 Dec 1;23(34):8629-35.

PMID:
16314625
10.

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA.

JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.

PMID:
26181175
11.

Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.

Kim D, Kang E, Hwang E, Sun Y, Hwang Y, Yom CK, Kim K, No JH, Kim YB, Kim SW.

Fam Cancer. 2013 Dec;12(4):621-8. doi: 10.1007/s10689-013-9625-z.

PMID:
23504064
12.

Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.

This P, de la Rochefordière A, Savignoni A, Falcou MC, Tardivon A, Thibault F, Alran S, Fourchotte V, Fitoussi A, Couturaud B, Dolbeault S, Salmon RJ, Sigal-Zafrani B, Asselain B, Stoppa-Lyonnet D; Institut Curie Breast and Ovarian Cancer Risk Study Group.

Fam Cancer. 2012 Sep;11(3):473-82. doi: 10.1007/s10689-012-9539-1.

PMID:
22711610
13.

Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL.

J Natl Cancer Inst. 1999 Sep 1;91(17):1475-9.

PMID:
10469748
14.

Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.

Finch A, Metcalfe K, Lui J, Springate C, Demsky R, Armel S, Rosen B, Murphy J, Elit L, Sun P, Narod S.

Clin Genet. 2009 Mar;75(3):220-4.

PMID:
19263514
15.

A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.

Sigal BM, Munoz DF, Kurian AW, Plevritis SK.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77. doi: 10.1158/1055-9965.EPI-12-0149. Epub 2012 May 3.

16.

Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer.

S Chapman J, Roddy E, Panighetti A, Hwang S, Crawford B, Powell B, Chen LM.

Clin Breast Cancer. 2016 Dec;16(6):494-499. doi: 10.1016/j.clbc.2016.06.016. Epub 2016 Jul 5.

PMID:
27495996
18.

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group.

N Engl J Med. 2002 May 23;346(21):1616-22. Epub 2002 May 20.

19.

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.

Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Blum JL, Domchek SM, Chen J, Rebbeck TR.

Breast Cancer Res Treat. 2014 Nov;148(2):397-406. doi: 10.1007/s10549-014-3134-0. Epub 2014 Oct 14.

20.

Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.

Collins IM, Milne RL, Weideman PC, McLachlan SA, Friedlander ML; Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer, Hopper JL, Phillips KA.

Med J Aust. 2013 Nov 18;199(10):680-3.

PMID:
24237098

Supplemental Content

Support Center